Who we are
US Telehealth Review publishes editorial reviews and rankings of GLP-1 telehealth providers in the United States, covering both semaglutide and tirzepatide. The editorial team is led by Dr. Sam Saberian (Lead Medical Researcher), with medical accuracy review by Alen A. Schwartz, MD (Medical Reviewer) and editorial review by Julliana Edwards (Editor). Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Rankings are based on the methodology, and providers cannot pay to appear higher in organic comparisons.
Dr. Sam Saberian — Lead Medical Researcher
Dr. Sam Saberian leads medical research for US Telehealth Review. Areas of focus: GLP-1 receptor agonist therapeutics, peptide pharmacology, and telehealth pharmacy traceability standards. Lead author of the v3.0 six-pillar transparency rubric used across all provider reviews on US Telehealth Review.
Alen A. Schwartz, MD — Medical Reviewer
Alen A. Schwartz, MD is a board-certified physician and Medical Reviewer for US Telehealth Review. Dr. Schwartz performs medical accuracy review on every provider review, clinical guide, and trial summary published on US Telehealth Review. His clinical focus spans GLP-1 receptor agonist therapeutics (semaglutide and tirzepatide), obesity medicine, and compounded sterile pharmacy oversight (USP <797>, 503A and 503B pathway distinctions). All medication safety claims and clinical disclosures are reviewed by Dr. Schwartz prior to publication.
Julliana Edwards — Editor
Julliana Edwards is the editor for US Telehealth Review. Reviews and edits all editorial content for accuracy, clarity, and adherence to the published rubric methodology before release. Leads the corrections process and quarterly methodology review.
Our scope
US Telehealth Review exclusively covers semaglutide and the broader GLP-1 / GIP therapeutic class. We cover:
- Semaglutide brand-name products: Ozempic, Wegovy, Rybelsus (all manufactured by Novo Nordisk)
- Compounded semaglutide dispensed via pharmacy fulfillment subject to availability
- Comparator GLP-1 / GIP medications: tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity)
- 10 U.S. semaglutide telehealth providers, scored against the v3.0 six-pillar transparency rubric
- FDA approvals, label expansions, and regulatory actions affecting the class
Why we exist — our editorial mission
The semaglutide telehealth landscape is fragmented and opaque. Patients face wide pricing variation ($99-$1,349/mo), inconsistent pharmacy disclosure, and unclear medical oversight. US Telehealth Review's mission is to provide patients with clear, sourced answers to a question existing review sites don't answer well: which semaglutide telehealth provider is actually right for me?
What US Telehealth Review is not
- Not a healthcare provider. We do not employ physicians, prescribe medications, or operate a pharmacy.
- Not a pharmacy or insurance broker.
- Not a substitute for medical advice. Information is educational.
- Not affiliated with the FDA, FTC, Novo Nordisk, Eli Lilly, or any government agency.
Contact & corrections
For corrections, provider-data updates, or to suggest a provider for review, email ustelehealthreview@gmail.com. We respond to documented corrections within 72 hours.
Alen A. Schwartz, MD
Medical Reviewer
Board-certified physician and Medical Reviewer for US Telehealth Review. Dr. Schwartz performs medical accuracy review on every provider review, clinical guide, and trial summary published on US Telehealth Review. His clinical focus spans GLP-1 receptor agonist therapeutics, obesity medicine, and compounded sterile pharmacy oversight (USP <797>, 503A and 503B pathway distinctions). All medication safety claims and clinical disclosures on US Telehealth Review are reviewed by Dr. Schwartz prior to publication.
Areas of expertise: Semaglutide and tirzepatide pharmacology, compounded GLP-1 quality assurance, obesity medicine, telehealth clinical protocols.